OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
September 17 2014 - 6:02AM
Business Wire
Former Senior Patent Counsel at Merck &
Co., Inc. to Oversee Global Legal Strategy
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, has appointed Sheela
Mohan-Peterson, J.D., M.S. to the position of General Counsel and
Corporate Secretary. In this newly created role, she will be
responsible for leading the Company’s global legal strategy and
guiding the continued expansion of its intellectual property
portfolio. Ms. Mohan-Peterson will be supported by an experienced
internal legal team that includes legal associate and paralegal
positions.
Punit Dhillon, President and CEO, said, “Sheela will be leading
our expanded legal department during a pivotal moment for the
Company. Her extensive legal expertise and strategic leadership
experience will allow us to aggressively pursue new intellectual
property and support the ongoing expansion of our R&D and
preclinical activities, as well as take the lead on negotiating
several business development opportunities.”
Ms. Mohan-Peterson has spent more than 27 years working in the
pharmaceutical and biotech industries, most recently as a Senior
Patent Counsel with Merck & Co., Inc. She received her
bachelor’s degree in biology from Washington University in St.
Louis, and her master’s degree in molecular biology from Rutgers
University. Ms. Mohan-Peterson began her career in 1986 as a
scientist in the Tumor Biology department of Schering-Plough
Research Institute in Bloomfield, New Jersey. In 1991, she
transferred to the Human Immunology department at DNAX Research
Institute, a subsidiary of Schering-Plough, located in Palo Alto,
California. After graduating from law school in 1997, she began her
career as a patent attorney at Incyte Genomics in Palo Alto, and
then as a patent counsel at Roche Bioscience, also in Palo
Alto. In 2000, she returned to DNAX as a senior patent counsel
and remained there for several years after a merger with Merck.
“I am very excited to be leading OncoSec’s legal department,”
said Ms. Mohan-Peterson. “In my new role, one of my major goals
will be to strengthen and expand OncoSec’s intellectual property,
which will establish a strong foundation to propel the company to
great success in the future.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical’s core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec’s clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Jordyn Kopin,
855-662-6732investors@oncosec.comorPublic Relations:Dian Griesel,
Int’l.Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024